Elicio Therapeutics
Cambridge
About Elicio Therapeutics
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $363.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:ELTX
- Website: elicio.com
- Phone: (617)945-2077
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/elicio-therapeutics-49815 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.